Extended Injection Intervals after Switching from Ranibizumab to Aflibercept in Macular Edema due to Central Retinal Vein Occlusion

Table 1

Demographics, baseline, and follow-up characteristics of patients with CRVO.

Demographics
Patients (eyes)	11 (11)
Mean age, years (range)	67.1 (44–83)
Women, n (%)	2 (18)
Diabetes, n (%)	1 (9)
Diabetic retinopathy, n (%)	1 (9)
Preswitch follow-up in months, mean (range)	23.4 (6–57)
Patients previously switched to steroid implant injections, n (range of injections)	3 (1–3)
Scatter panretinal photocoagulation, n (%)	3 (27%)
Previous ranibizumab injections number, mean ± SD	15.3 ± 9.8
Aflibercept injections number after switch, mean ± SD	12.4 ± 4.2
Postswitch follow-up, in month, mean (range)	25.5 (16–38)